Olaparib
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
<scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | <scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | ||
| + | See also: | ||
| + | *[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | ||
| + | *[[Mutations in Brca1 BRCT Domains]] | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 06:25, 19 October 2023
| |||||||||||
References
- ↑ Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. PMID:19553641 doi:10.1056/NEJMoa0900212
